In addition, clinical studies of c‐Src inhibitors have been initiated in patients with bone metastases, since c‐Src plays multiple roles in the bone resorption and in the proliferation, survival, metastasis of breast cancer cells.24, 25 Unfortunately, the efficiency of c‐Src inhibitors has not been generally encouraging in clinical trials to date. Here, SRC is linked to breast cancer.